{"pmid":32304139,"title":"Progress and Concept for COVID-19 Vaccine Development.","text":["Progress and Concept for COVID-19 Vaccine Development.","Biotechnol J","Wu, Suh-Chin","32304139"],"journal":"Biotechnol J","authors":["Wu, Suh-Chin"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32304139","week":"202016|Apr 13 - Apr 19","doi":"10.1002/biot.202000147","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664431720467791872,"score":8.233237,"similar":[{"pmid":32235387,"title":"Progress and Prospects on Vaccine Development against SARS-CoV-2.","text":["Progress and Prospects on Vaccine Development against SARS-CoV-2.","In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2.","Vaccines (Basel)","Zhang, Jinyong","Zeng, Hao","Gu, Jiang","Li, Haibo","Zheng, Lixin","Zou, Quanming","32235387"],"abstract":["In December 2019, the outbreak of pneumonia caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a serious pandemic in China and other countries worldwide. So far, more than 460,000 confirmed cases were diagnosed in nearly 190 countries, causing globally over 20,000 deaths. Currently, the epidemic is still spreading and there is no effective means to prevent the infection. Vaccines are proved to be the most effective and economical means to prevent and control infectious diseases. Several countries, companies, and institutions announced their programs and progress on vaccine development against the virus. While most of the vaccines are under design and preparation, there are some that have entered efficacy evaluation in animals and initial clinical trials. This review mainly focused on the progress and our prospects on field of vaccine development against SARS-CoV-2."],"journal":"Vaccines (Basel)","authors":["Zhang, Jinyong","Zeng, Hao","Gu, Jiang","Li, Haibo","Zheng, Lixin","Zou, Quanming"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32235387","week":"202014|Mar 30 - Apr 05","doi":"10.3390/vaccines8020153","keywords":["SARS-CoV-2","adjuvant","animal model","vaccine"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1663352135491780608,"score":83.05179},{"pmid":32234130,"title":"[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","text":["[Progress and challenge of vaccine development against 2019 novel coronavirus (2019-nCoV)].","The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated.","Zhonghua Yu Fang Yi Xue Za Zhi","Shi, Y","Wang, N","Zou, Q M","32234130"],"abstract":["The outbreak of 2019 novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same beta-genus of coronavirus family. Base on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over the world are working hard and quickly on the related fields. There are substantial progress in these fields including the characterizing the 2019-nCoV virus, identification of candidate antigens and epitopes, establishment of animal models, characterizing the immune responses, and the design of vaccines. The development of 2019-nCoV vaccines cover all types: inactivated virus vaccine, recombinant protein vaccine, viral vector-based vaccine, mRNA vaccine, and DNA vaccine, et al. As of March 2020, two 2019-nCoV vaccines have entered phase I clinical trials. One is named as Ad5-nCoV developed by the Chinese Institute of Biotechnology of the Academy of Military Medical Sciences and Tianjin Cansino Biotechnology Inc. Ad5-nCoV is based on the replication-defective adenovirus type 5 as the vector to express 2019-nCoV spike protein. The another vaccine is mRNA-1273 developed by the National Institute of Allergy and Infectious Diseases and Moderna, Inc.. RNA-1273 is an mRNA vaccine expressing 2019-nCoV spike protein. Although the rapid development of 2019-nCoV vaccine, it still faces many challenges with unknown knowledge, including the antigenic characteristics of the 2019-nCoV, the influence of antigenic variation, the protective immune response of host, the protection of the elderly population, and the downstream manufacturing process of the new vaccine. The safety and efficacy of vaccines are the first priority for vaccine development and should be carefully evaluated."],"journal":"Zhonghua Yu Fang Yi Xue Za Zhi","authors":["Shi, Y","Wang, N","Zou, Q M"],"date":"2020-04-03T11:00:00Z","year":2020,"_id":"32234130","week":"202014|Mar 30 - Apr 05","doi":"10.3760/cma.j.cn112150-20200317-00366","keywords":["2019-nCoV","Animal models","Vaccine"],"source":"PubMed","locations":["Moderna"],"topics":["Mechanism","Treatment"],"weight":1,"_version_":1663352135484440576,"score":76.221535},{"pmid":32273591,"title":"The COVID-19 vaccine development landscape.","text":["The COVID-19 vaccine development landscape.","Nat Rev Drug Discov","Thanh Le, Tung","Andreadakis, Zacharias","Kumar, Arun","Gomez Roman, Raul","Tollefsen, Stig","Saville, Melanie","Mayhew, Stephen","32273591"],"journal":"Nat Rev Drug Discov","authors":["Thanh Le, Tung","Andreadakis, Zacharias","Kumar, Arun","Gomez Roman, Raul","Tollefsen, Stig","Saville, Melanie","Mayhew, Stephen"],"date":"2020-04-11T11:00:00Z","year":2020,"_id":"32273591","week":"202015|Apr 06 - Apr 12","doi":"10.1038/d41573-020-00073-5","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663712077909327872,"score":61.481678},{"pmid":32227757,"title":"Developing Covid-19 Vaccines at Pandemic Speed.","text":["Developing Covid-19 Vaccines at Pandemic Speed.","N Engl J Med","Lurie, Nicole","Saville, Melanie","Hatchett, Richard","Halton, Jane","32227757"],"journal":"N Engl J Med","authors":["Lurie, Nicole","Saville, Melanie","Hatchett, Richard","Halton, Jane"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32227757","week":"202014|Mar 30 - Apr 05","doi":"10.1056/NEJMp2005630","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352135241170944,"score":58.51314},{"pmid":32148172,"title":"Timely development of vaccines against SARS-CoV-2.","text":["Timely development of vaccines against SARS-CoV-2.","Emerg Microbes Infect","Lu, Shan","32148172"],"journal":"Emerg Microbes Infect","authors":["Lu, Shan"],"date":"2020-03-10T11:00:00Z","year":2020,"_id":"32148172","week":"202011|Mar 09 - Mar 15","doi":"10.1080/22221751.2020.1737580","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1663352134141214722,"score":58.09283}]}